Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Via Francesco Sforza, 35, 20143, Milano, Italy.
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
J Endocrinol Invest. 2022 Jan;45(1):9-16. doi: 10.1007/s40618-021-01605-5. Epub 2021 Jun 11.
Patients with Cushing's syndrome (CS) are at high risk of venous thromboembolism related to a hypercoagulability due to procoagulant imbalance. However, whether these alterations are reversible after disease remission is still unclear. The endogenous thrombin potential (ETP) measured with and without the addition of thrombomodulin provides a global representation of coagulation and previous data confirmed hypercoagulable profile in patients with active hypercortisolism. Aim of this study was to assess the short- and long-term modification of ETP in patients with CS after disease remission.
Nineteen patients with CS for whom surgical remission was achieved, were prospectively evaluated for clinical characteristics, cortisol secretion profile and ETP at different time points: (i) before surgical intervention; (ii) after 6 months and (iii) 5 years from the time of persistent remission. Nineteen healthy subjects matched for age and gender were also evaluated as control group.
Before surgery, patients showed higher ETP-ratio (with/without thrombomodulin) than controls (0.62 ± 0.09-vs-0.56 ± 0.09, p = 0.034). No significant correlation between ETP-ratio and cortisol secretion was found. 6 months after remission, ETP-ratio was still significantly increased compared to controls (0.64 ± 0.09-vs-0.56 ± 0.09, p = 0.01), but was similar to baseline (0.64 ± 0.09-vs-0.62 ± 0.09, p = 0.87). At 5 years, ETP-ratio showed a significant decrease (0.55 ± 0.14-vs-0.62 ± 0.09, p = 0.02) and was comparable to controls (0.55 ± 0.14-vs-0.56 ± 0.09, p = 0.7).
Plasma hypercoagulability detected in patients with active hypercortisolism persists at short-term evaluation and seems to be completely reversible after long-term remission of disease. These data, as part of a whole evaluation of thrombotic risk, can contribute to make appropriate therapeutic choice in these patients.
由于促凝失衡,库欣综合征(CS)患者存在静脉血栓栓塞的高风险,与高凝状态有关。然而,疾病缓解后这些改变是否可逆仍不清楚。使用和不使用血栓调节蛋白测量的内源性凝血酶潜能(ETP)提供了凝血的整体表现,先前的数据证实了活动性高皮质醇血症患者的高凝状态。本研究旨在评估 CS 患者在疾病缓解后 ETP 的短期和长期变化。
前瞻性评估 19 例接受手术缓解的 CS 患者的临床特征、皮质醇分泌特征和不同时间点的 ETP:(i)手术前;(ii)术后 6 个月;(iii)持续缓解 5 年后。还评估了 19 名年龄和性别匹配的健康受试者作为对照组。
术前,患者的 ETP-比值(加/不加血栓调节蛋白)高于对照组(0.62±0.09-vs-0.56±0.09,p=0.034)。未发现 ETP-比值与皮质醇分泌之间存在显著相关性。缓解后 6 个月,ETP-比值仍明显高于对照组(0.64±0.09-vs-0.56±0.09,p=0.01),但与基线相似(0.64±0.09-vs-0.62±0.09,p=0.87)。5 年后,ETP-比值显著下降(0.55±0.14-vs-0.62±0.09,p=0.02),与对照组相当(0.55±0.14-vs-0.56±0.09,p=0.7)。
在活动性高皮质醇血症患者中检测到的血浆高凝状态在短期评估时持续存在,并且在疾病长期缓解后似乎完全可逆。这些数据作为血栓形成风险全面评估的一部分,可以帮助这些患者做出适当的治疗选择。